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Current guidelines recommend against the use of phenytoin following aneurysmal subarachnoid hemor-
rhage (aSAH) but consider other anticonvulsants, such as levetiracetam, acceptable. Our objective was to
evaluate the risk of poor functional outcomes, delayed cerebral ischemia (DCI) and delayed seizures in
aSAH patients treated with levetiracetam versus phenytoin. Medical records of patients with aSAH admit-
ted between 2005–2012 receiving anticonvulsant prophylaxis with phenytoin or levetiracetam for
>72 hours were reviewed. The primary outcome measure was poor functional outcome, deﬁned as mod-
iﬁed Rankin Scale (mRS) score >3 at ﬁrst recorded follow-up. Secondary outcomes measures included DCI
and the incidence of delayed seizures. The association between the use of levetiracetam and phenytoin
and the outcomes of interest was studied using logistic regression. Medical records of 564 aSAH patients
were reviewed and 259 included in the analysis after application of inclusion/exclusion criteria. Phenytoin
was used exclusively in 43 (17%), levetiracetam exclusively in 132 (51%) while 84 (32%) patients were
switched from phenytoin to levetiracetam. Six (2%) patients had delayed seizures, 94 (36%) developed DCI
and 63 (24%) had mRS score >3 at follow-up. On multivariate analysis, only modiﬁed Fisher grade and
seizure before anticonvulsant administration were associatedwith DCI while age, Hunt-Hess grade and pres-
ence of intraparenchymal hematoma were associated with mRS score >3. Choice of anticonvulsant was not
associated with any of the outcomes of interest. There was no difference in the rate of delayed seizures, DCI
or poor functional outcome in patients receiving phenytoin versus levetiracetam after aSAH. The high rate of
crossover from phenytoin suggests that levetiracetam may be better tolerated.
 2014 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-SA
license (http://creativecommons.org/licenses/by-nc-sa/3.0/).1. Background
Anticonvulsant prophylaxis is widely used following aneurys-
mal subarachnoid hemorrhage (aSAH). Retrospective studies
report the rate of seizures after aSAH to be between 1–18% [1–6].
The incidence of delayed or in-hospital seizures may be even
lower, 4–8%, when anticonvulsant prophylaxis is used [4–6]. It is
not known whether the choice of anticonvulsant used for prophy-
laxis has an impact on the subsequent risk of seizures or poor
outcomes after aSAH. A retrospective study of patients with aSAH
found that phenytoin burden may be associated with poor cogni-tive outcome at 3 months [7]. Current guidelines from the Neuro-
critical Care Society (NCS) therefore speciﬁcally recommend
against the routine use of phenytoin for prophylaxis [2], while
the American Heart Association guidelines state that the use of
anticonvulsants is reasonable, without speciﬁcally recommending
against or for any particular anticonvulsant [1]. Unlike the case
with phenytoin, the NCS guidelines do not speciﬁcally recommend
against the use of other anticonvulsants, and state that alternate
anticonvulsants may be considered for prophylaxis for a duration
of 3–7 days from ictus [2,3]. While levetiracetam is a popular alter-
native to phenytoin, the relative value of alternate anticonvulsants
such as levetiracetam has not been systematically addressed, and it
is not clear that their routine use is associated with better
outcomes compared to the use of phenytoin in this speciﬁc setting.
One study suggests that the short term use of levetiracetammay be
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a longer duration of prophylaxis with phenytoin [8]. To our knowl-
edge the speciﬁc risk of delayed cerebral ischemia (DCI) with
levetiracetam versus that with phenytoin has also not been system-
atically evaluated – a relevant question in view of the association
between phenytoin burden, fever and poor outcomes [7,9,10]. It
is also possible that a less efﬁcacious anticonvulsant may increase
the risk of DCI through the mechanism of delayed seizures and
increased metabolic demand, as has been previously described
[11]. One animal study has demonstrated a decreased risk of poor
neurological outcomes as well as vasospasm associated with the
use of levetiracetam after aSAH [12]. To our knowledge there is
no study in the literature directly comparing the risk of delayed
seizures, DCI and poor outcomes associated with the use of leveti-
racetam versus phenytoin in patients with aSAH.
We aimed to compare the rate of poor functional outcomes,
delayed seizures and DCI in patients treated with phenytoin versus
levetiracetam following aSAH.2. Methods
Approval for this study was obtained from the University of
Michigan’s Institutional Review Board (HUM00050017). The med-
ical records of patients with an aSAH admitted between January
2005 and February 2012 were reviewed. Patients with aSAH
receiving phenytoin or levetiracetam for at least 72 hours follow-
ing admission were included. Patients with non-aneurysmal etiol-
ogy, age <18 years, non-availability of CT scan within 24 hours of
onset, modiﬁed Fisher grade 0–1, those who died within 72 hours
and patients with a pre-existing seizure disorder were excluded.2.1. Outcomes of interest
The primary outcome of interest was poor functional outcome
at ﬁrst recorded follow-up. Follow-up was assessed between
6 weeks and 6 months from discharge or at date of last contact fol-
lowing discharge. The modiﬁed Rankin Scale (mRS) [13] score was
used to assess functional outcome at follow-up, based on speciﬁc
documentation at the time of Rehabilitation, Neurosurgery and
Neurology clinic visits. Poor neurological outcome was deﬁned as
mRS score >3. The secondary outcomes of interest were the inci-
dence of seizures following initiation of anticonvulsant prophy-
laxis (delayed seizures) and the occurrence of DCI. Both clinically
apparent as well as non-convulsive seizures detected only on elec-
troencephalography (EEG) were included when determining the
incidence of delayed seizures. Continuous EEG monitoring (cEEG)
was not routinely performed, however, and was requested only
at the discretion of the treating physician. DCI was deﬁned as the
composite of symptomatic vasospasm and/or delayed infarction
on imaging [14]. Symptomatic vasospasm was deﬁned as a change
in neurological status during days 3–14 consisting of neurological
worsening lasting P2 hours. Neurological worsening was deﬁned
as modiﬁed Glasgow Coma Scale score decline by 2 or more points,
an increase by 2 or more points on the abbreviated National Insti-
tutes of Health Stroke Scale, or a new focal neurological deﬁcit or
new hypodensity on head CT scan with clinical signs. Symptoms
must not have been explained by hydrocephalus, surgical trauma,
new hemorrhage, recognized seizure, fever, sedation, hypoxia,
infection, or metabolic abnormality, and must have been thought
to be due to symptomatic vasospasm by the treating team, includ-
ing the attending neurointensivist and neurosurgeon. Delayed
infarction was documented on head CT scan between day 3 and
6 weeks from ictus and could not be procedure related.2.2. Variables of interest
The primary variables of interest were the use of phenytoin or
levetiracetam for at least 72 hours within the ﬁrst week after aSAH.
Seventy-two hours was considered the threshold for ‘‘signiﬁcant’’
use of phenytoin and other anticonvulsants since some authors
as well as the current guidelines from the NCS recommend that
anticonvulsant use following aSAH be conﬁned to a 3–7 day period
[2,15]. All changes from one anticonvulsant to another were
recorded, along with the reason for the change if documented in
the medical record.
All seizures that occurred in the risk period for delayed cerebral
ischemia (up to 21 days from admission), including those observed
in the pre-hospital setting and emergency room prior to anticon-
vulsant initiation, as well any seizures occurring following initia-
tion of anticonvulsant therapy (delayed seizures), were recorded
and analyzed as variables in association with the outcomes of
DCI and poor functional outcome. We analyzed the occurrence of
seizures in these two different clinical settings (i.e, seizures occur-
ring pre and post-initiation of anticonvulsant) as separate variables
in association with the outcomes of interest since the pathophysi-
ology, prognostic signiﬁcance and implications for treatment are
potentially very different for seizures occurring at the time of ictus
versus those occurring at a later time despite the use of anticonvul-
sant prophylaxis. Other variables analyzed for association with
delayed cerebral ischemia and poor functional outcome were age,
race, sex, smoking history, history of hypertension, Hunt and Hess
grade [16], modiﬁed Fisher grade [17], presence of intracerebral
hematoma, aneurysm location, aneurysm size and the use of
clipping versus coiling.
2.3. Management protocol
Every effort was made to secure the aneurysm with microsurgi-
cal clipping or endovascular coiling within 24 hours of admission.
All patients were admitted to the neuro-intensive care unit for
monitoring. External ventricular drainage was performed for
hydrocephalus. Anticonvulsants were started on admission for all
patients, continued for the duration of the inpatient admission
and tapered off within 30 days following discharge, unless the
patient had suffered a seizure and required ongoing anticonvulsant
use. Choice of anticonvulsant was at the discretion of the attending
neurosurgeon or neurointensivist. Phenytoin was typically initi-
ated with a 20 mg/kg intravenous load and then continued at a
dose of 4–6 mg/kg/day. Phenytoin levels were not routinely mea-
sured on a daily basis and were ordered intermittently at the dis-
cretion of the treating physician. Aggressive supplementation to
maintain ‘‘therapeutic’’ levels was not routinely performed and
the phenytoin burden could not therefore be reliably estimated.
Levetiracetam was typically initiated at 250–500 mg twice daily
and further dose adjustments were at the discretion of the treating
physician. cEEG monitoring was ordered at the discretion of the
treating physician. Nimodipine was used in all patients for 21 days
if hemodynamically tolerated. A magnesium infusion (ﬁxed dose of
0.5 g/hour) was used in all patients for 14 days. The infusion was
not titrated to target levels and serum levels were measured incon-
sistently. The goal of ﬂuid management was euvolemia using nor-
mal saline in all patients. Patients with otherwise unexplained
acute neurological deterioration were given a bolus of crystalloid
or colloid and had their blood pressure augmented by 20–30%
using vasopressors. Augmentation of cardiac index was variably
performed. Angiographic imaging with either digital subtraction
angiography or CT angiography was performed as soon as possible
in all patients with neurological deterioration following a non-
contrast head CT scan, regardless of response to hemodynamic
augmentation.
Table 1
Distribution of variables in patients with and without delayed cerebral ischemia
(n = 259)
Variable Delayed cerebral
ischemia absent
Delayed cerebral
ischemia present
p value
n = 165 n = 94
Age, years, mean ± SD 56 ± 14 55 ± 12 0.94
Female sex 121 (73%) 71 (76%) 0.81
Race 0.66
Asian 5 1
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The D’Agostino–Pearson test was used to determine if variables
demonstrated normal distribution. Mean and standard deviation
(SD) with range was calculated for continuous variables with nor-
mal distribution. For variables without normal distribution, the
median with interquartile range was used. To test whether there
was a bivariate association between categorical patient variables
and the outcomes of interest, chi-squared or Fisher’s exact test
was used. Bivariate associations of continuous patient variables
with a normal distribution were assessed with the independent
sample two-tailed Student’s t-test and continuous variables with
non-normal distributions were assessed with the Mann–Whitney
U test. Multivariate logistic regression models to identify indepen-
dent associations among variables of interest and the outcomes of
interest were built. With our explanatory variables of interest
(exposure to phenytoin and levetiracetam) and occurrence of sei-
zures before and after anticonvulsant use forced into the models,
additional covariates were chosen based on an association with
DCI or functional outcome using a liberal threshold of approxi-
mately p < 0.2 on unadjusted bivariate analysis. In addition to the
multivariate analysis to examine the association of exposure to
phenytoin and levetiracetam for P72 hours with the outcomes of
interest, we also performed a predetermined multivariate analysis
of the association between the choice of anticonvulsant (phenytoin
OR levetiracetam, as a single variable) and outcomes of interest in
the subgroup of patients treated with a single anticonvulsant for
the entire course of their admission, to exclude the confounding
effect of crossover from one anticonvulsant to another. Statistical
analyses were performed using MedCalc version 12.7.5.0 (MedCalc
software, Mariakerke, Belgium).Black 13 8
Caucasian 136 81
Hispanic 2 0
Other 9 4
Smoker 81 (49%) 47 (50%) 0.99
Hypertension history 72 (44%) 49 (52%) 0.25
Hunt and Hess grade 0.0001*
1 29 (18%) 7 (7%)
2 57 (35%) 19 (20%)
3 45 (26%) 32 (34%)
4 18 (11%) 30 (32%)
5 16 (10%) 6 (6%)
Modiﬁed Fisher grade <0.0001*
2 19 (11%) 3 (3%)
3 120 (73%) 50 (53%)
4 26 (16%) 41 (44%)
Intracerebral hematoma 34 (21%) 31 (33%) 0.04*
Aneurysm artery location 0.38
Anterior
communicating
47 37
Posterior
communicating
40 25
Middle cerebral 26 11
Posterior inferior
cerebellar
11 6
Internal carotid 15 8
Basilar 13 4
Other 13 3
Aneurysm size, median
(interquartile range)
6 mm (4–8) 6 mm (4–9) 0.95
Microsurgical clipping
performed
83 (50%) 49 (52%) 0.09*
Phenytoin use P72 hours 83 (50%) 44 (47%) 0.68*
Levetiracetam use
P72 hours
135 (81%) 81 (86%) 0.46*
Seizure before
anticonvulsant
8 (5%) 13 (14%) 0.02*
Seizure after
anticonvulsant
4 (2%) 2 (2%) 1.00*
Data are presented as n (%) unless otherwise stated.
SD = standard deviation.
* Included in multivariate analysis.3. Results
The medical records of 564 patients with subarachnoid hemor-
rhage were reviewed. Of these, 559 received at least 72 hours of
either phenytoin or levetiracetam in the ﬁrst week after aSAH.
One hundred ﬁfty-one were excluded based on non-aneurysmal
etiology, 98 based on the absence of initial CT scan and/or death
within 72 hours of admission, and 51 for modiﬁed Fisher grade
0–1 on initial CT scan. Two hundred ﬁfty-nine patients with aSAH
met criteria and were included in the analysis. The mean age was
55 years (SD 13 years, range 23–90). There were 192 (74%) women
and 67 (26%) men.
3.1. Anticonvulsant use
Of the 259 patients who were studied, 127 (49%) received phe-
nytoin for at least 72 hours following admission while levetirace-
tam was used for P72 hours following admission in 132 (51%).
Of the 127 patients initially treated with phenytoin, 84 (66%) were
subsequently changed over to levetiracetam. No patient was chan-
ged from levetiracetam to phenytoin. Of the 84 patients who were
switched from phenytoin to levetiracetam during their hospital
stay, 30 had a reason for the change documented in medical
records. Twelve were documented as having been changed for
fever alone, 10 were changed because of difﬁculty maintaining
therapeutic serum levels of phenytoin, ﬁve for the appearance of
a new rash, two for both fever and a new rash, and one in an
attempt to optimize cognitive recovery.
3.2. Seizures
Twenty-seven of 259 patients (10%) had seizures at any time
after aneurysm rupture. Twenty-one (8% of all patients) had atleast one clinical seizure in the ﬁeld or in the emergency room
prior to administration of an anticonvulsant. Of these patients, 12
were loaded with phenytoin on arrival to the hospital while nine
were treated with levetiracetam. Six of 259 (2%) patients had a sei-
zure following initiation of anticonvulsant prophylaxis (delayed
seizures). All were overt clinical seizures, there were no isolated
electrographic/non-convulsive seizures documented in our series.
Three patients were on phenytoin at the time of their seizure,
occurring 2, 7 and 10 days after admission. One patient had a
seizure 11 days after admission, 6 days after being switched to
levetiracetam from phenytoin. Two other patients had seizures
while on levetiracetam, at 2 and 10 days following admission. All
pre-anticonvulsant seizures were recorded as being generalized
tonic-clonic. The clinical manifestation of all delayed seizures
included a transient decrease in the level of alertness with varied
motor manifestations. Motor manifestations were generalized
tonic-clonic (one patient), posturing (three patients), eye deviation
(one patient), eye deviation plus arm jerking (one patient) and
rhythmic facial twitching (one patient). No patient had both a pre-
anticonvulsant seizure as well as seizure after starting anticonvulsant.
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sure to phenytoin P72 hours (p = 0.44) and occurrence of delayed
seizures. There was a trend toward fewer seizures in patients
exposed to levetiracetam P72 hours (p = 0.06), with 3/216 (1%)
patients exposed to levetiracetam versus 3/43 (7%) never exposed
to levetiracetam suffering delayed seizures; however, the predeter-
mined threshold for statistical signiﬁcance (p < 0.05) was not
reached. In the subgroup of patients treated with a single anticon-
vulsant for the duration of their admission, again there was no sta-
tistically signiﬁcant association between choice of anticonvulsant
(phenytoin OR levetiracetam) and occurrence of delayed seizures
(p = 0.10). The number of delayed seizures (n = 6) was too small
to permit meaningful multivariate analysis.3.3. DCI
Overall, 94 of 259 (36%) patients had DCI. Table 1 depicts the
distribution of variables in patients with and without DCI. Hunt
and Hess grade, modiﬁed Fisher grade, presence of intracerebralTable 2
Distribution of variables in patients treated exclusively with one anticonvulsant with
and without delayed cerebral ischemia
Variable Delayed cerebral
ischemia absent
Delayed cerebral
ischemia present
p value
n = 112 n = 63
Age, years, mean ± SD 57 ± 14 55 ± 13 0.33
Female sex 83 (74%) 47 (75%) 0.91
Race 0.77
Asian 3 1
Black 7 3
Caucasian 95 57
Hispanic 2 0
Other 5 2
Smoker 51 (46%) 30 (48%) 0.91
Hypertension history 50 (45%) 32 (51%) 0.57
Hunt and Hess grade 0.0008*
1 19 (17%) 6 (10%)
2 36 (32%) 12 (19%)
3 31 (28%) 22 (35%)
4 12 (11%) 20 (32%)
5 14 (13%) 3 (5%)
Modiﬁed Fisher grade 0.0008*
2 14 (13%) 2 (3%)
3 80 (71%) 36 (57%)
4 18 (16%) 25 (39%)
Intracerebral hematoma 25 (22%) 19 (30%) 0.33
Aneurysm artery
location
0.49
Anterior
communicating
26 23
Posterior
communicating
33 19
Middle cerebral 14 6
Posterior inferior
cerebellar
8 4
Internal carotid 12 6
Basilar 6 2
Other 13 3
Aneurysm size, median
(interquartile range)
5.65 mm (4–8) 6 mm (4–8.3) 0.64
Microsurgical clipping
performed
53 (47%) 30 (48%) 0.03*
Phenytoin as
anticonvulsant
30 (27%) 13 (21%) 0.47*
Seizure before
anticonvulsant
7 (6%) 9 (14%) 0.13*
Seizure after
anticonvulsant
3 (3%) 2 (3%) 0.78*
Data are presented as n (%) unless otherwise stated.
SD = standard deviation.
* Included in multivariate analysis.hematoma, performance of microsurgical clipping and seizure
prior to anticonvulsant use attained the p < 0.2 threshold on bivar-
iate analysis for inclusion in the multivariate model. When these
variables, plus use of phenytoin, use of levetiracetam, seizure prior
to anticonvulsant use and seizure after anticonvulsant initiation
were included in a multivariate logistic regression analysis, only
modiﬁed Fisher grade 4 (odds ratio [OR] 4.47, 95% conﬁdence
interval [CI] 2.18–9.13, p < 0.0001) and seizure before anticonvul-
sant administration (OR 6.30, 95% CI 2.01–19.76, p = 0.002) were
found to attain statistical signiﬁcance for association with DCI. In
the multivariate analysis of patients treated with only one anticon-
vulsant through the course of their hospital stay (n = 175, Table 2),
again only modiﬁed Fisher grade 4 (OR 4.22, 95% CI 1.70–10.45,
p = 0.002) and seizure before anticonvulsant administration (OR
4.62, 95% CI 1.13–18.80, p = 0.03) were found to attain statistical
signiﬁcance for association with DCI.
The two components of DCI, symptomatic vasospasm (n = 81)
and delayed infarction (n = 57) were found in 31% (86% of patients
with DCI) and 22% (61% of patients with DCI) of all patients, respec-
tively. Forty-four patients (17% of all patients, 47% of patients with
DCI) had both symptomatic vasospasm and DCI. The distribution of
seizures and anticonvulsant use in patients with and without
symptomatic vasospasm and delayed infarction is shown in
Table 3. Seizure prior to anticonvulsant use was the only variable
to attain statistical signiﬁcance on bivariate analysis, with most
of the association with DCI resulting from a statistically signiﬁcant
association (p = 0.01) with delayed infarction.3.4. Poor neurological outcome
Of 259 patients, 63 (24%) had mRS score >3 at follow up. Table 4
depicts the distribution of variables in patients with and without
mRS score >3. Age, smoking history, history of hypertension, Hunt
and Hess grade, modiﬁed Fisher grade, presence of intracerebral
hematoma and treatment modality (coiling versus microsurgical
clipping) attained the p < 0.2 threshold on bivariate analysis for
inclusion in the multivariate analysis, along with the forced inclu-
sion of the variables of interest – use of phenytoin, use of leveti-
racetam, seizure prior to anticonvulsant use and seizure after
anticonvulsant initiation. Following logistic regression age (ORTable 3
Distribution of seizures and anticonvulsant use in patients with and without
symptomatic vasospasm and delayed infarction
Variable Symptomatic
vasospasm present
Symptomatic
vasospasm absent
p value
n = 81 n = 178
Phenytoin use
P72 hours
39 (48%) 88 (49%) 0.95
Levetiracetam use
P72 hours
70 (86%) 146 (82%) 0.48
Seizure before
anticonvulsant
10 (12%) 11 (6%) 0.15
Seizure after
anticonvulsant
1 (1%) 5 (3%) 0.67
Variable Delayed infarct
present
Delayed infarct
absent
p value
n = 57 n = 202
Phenytoin use
P72 hours
26 (46%) 101 (50%) 0.66
Levetiracetam use
P72 hours
47 (82%) 169 (84%) 0.99
Seizure before
anticonvulsant
10 (18%) 11 (5%) 0.01
Seizure after
anticonvulsant
2 (4%) 4 (2%) 0.62
Data are presented as n (%).
Table 5
Distribution of variables in patients treated exclusively with one anticonvulsant with
and without poor functional outcome
Variable Good functional
outcome (mRS
score 6 3)
Poor functional
outcome (mRS
score > 3)
p value
n = 126 n = 49
Age, years,
mean ± SD
53 ± 12 63 ± 14 <0.0001*
Female sex 90 (71%) 40 (82%) 0.23
Race 0.74
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95% CI 0.001–0.35, p = 0.008), Hunt and Hess grade 5 (OR 23.60,
95% CI 4.76–117.02, p = 0.0001) and presence of intraparenchymal
hematoma (OR 3.86, 95% CI 1.56–9.59, p = 0.004) were associated
with poor functional outcome. In the multivariate analysis of
patients treated with only one anticonvulsant through the course
of their hospital stay (n = 175, Table 5), only age (OR 1.11, 95% CI
1.05–1.18, p = 0.0002) and presence of intraparenchymal hema-
toma (OR 14.96, 95% CI 3.60–62.16, p = 0.0002) attained statistical
signiﬁcance for association with mRS score >3.Asian 3 1
Black 8 2
Caucasian 107 45
Hispanic 2 0
Other 6 3
Smoker 62 (49%) 19 (39%) 0.28
Hypertension
history
85 (67%) 36 (73%) 0.25
Hunt and Hess grade <0.0001*
1 25 (20%) 0 (0%)
2 45 (36%) 3 (6%)
3 37 (29%) 16 (33%)
4 19 (15%) 13 (27%)
5 0 (0%) 17 (35%)4. Discussion
Our study, which to our knowledge is the ﬁrst to directly com-
pare outcomes related to levetiracetam versus phenytoin use in the
setting of aSAH, found no signiﬁcant difference in the rates of
delayed seizures, DCI and poor functional outcome. While a ran-
domized controlled trial of phenytoin versus levetiracetam in a
mixed group of patients, 89% of whom had severe traumatic brain
injury, found improved neurological and functional outcomes in
patients treated with levetiracetam with no difference in theTable 4
Distribution of variables in all patients with and without poor functional outcome
(modiﬁed Rankin Scale score >3)
Variable Good functional
outcome
Poor functional
outcome
p value
n = 196 n = 63
Age, years, mean ± SD 53 ± 12 63 ± 14 <0.0001*
Female sex 143 (73%) 49 (78%) 0.55
Race 0.93
Asian 5 1
Black 16 5
Caucasian 163 54
Hispanic 2 0
Other 10 3
Smoker 104 (63%) 24 (38%) 0.05*
Hypertension history 85 (52%) 36 (57%) 0.08*
Hunt and Hess grade <0.0001*
1 35 (18%) 1 (2%)
2 70 (42%) 6 (10%)
3 58 (35%) 19 (31%)
4 30 (18%) 18 (29%)
5 3 (2%) 19 (31%)
Modiﬁed Fisher grade 0.04*
2 17 (9%) 5 (8%)
3 136 (69%) 34 (54%)
4 43 (22%) 24 (38%)
Intracerebral hematoma 33 (20%) 32 (51%) <0.0001*
Aneurysm artery location 0.44
Anterior communicating 68 16
Posterior communicating 44 21
Middle cerebral 29 8
Posterior inferior
cerebellar
12 5
Internal carotid 17 6
Basilar 15 2
Other 11 5
Aneurysm size, median
(interquartile range)
6 mm (4–8) 6 mm (4–9) 0.44
Microsurgical clipping
performed
112 (57%) 20 (32%) <0.0001*
Delayed cerebral ischemia 69 (35%) 25 (40%) 0.62
Phenytoin use P72 hours 100 (51%) 27 (43%) 0.33*
Levetiracetam use
P72 hours
166 (85%) 50 (79%) 0.43*
Seizure before
anticonvulsant
13 (7%) 8 (13%) 0.20*
Seizure after anticonvulsant 4 (0.02%) 2 (0.03%) 0.97*
Data are presented as n (%) unless otherwise stated.
SD = standard deviation.
* Included in multivariate analysis.
Modiﬁed Fisher
grade
0.02*
2 13 (10%) 3 (6%)
3 89 (71%) 27 (55%)
4 24 (19%) 19 (39%)
Intracerebral
hematoma
18 (14%) 26 (53%) <0.0001*
Aneurysm artery
location
0.50
Anterior
communicating
39 10
Posterior
communicating
33 19
Middle cerebral 16 4
Posterior inferior
cerebellar
8 4
Internal carotid 12 6
Basilar 7 1
Other 11 5
Aneurysm size,
median
(interquartile
range)
5.1 mm (4–8) 6 mm (4.68–8.63) 0.16*
Microsurgical
clipping
performed
68 (54%) 15 (31%) <0.0001*
Delayed cerebral
ischemia
44 (35%) 19 (39%) 0.76
Phenytoin as
anticonvulsant
30 (24%) 13 (27%) 0.86*
Seizure before
anticonvulsant
9 (7%) 7 (14%) 0.15*
Seizure after
anticonvulsant
3 (0.02%) 2 (0.04%) 0.62*
Data are presented as n (%) unless otherwise stated.
mRS = modiﬁed Rankin Scale, SD = standard deviation.
* Included in multivariate analysis.seizure rate, no similar clinical trial has been conducted in the spe-
ciﬁc setting of aSAH [18]. In our study, delayed seizures were rare
when anticonvulsant prophylaxis was used with either levetirace-
tam or phenytoin. Only six of 259 (2%) patients had a seizure fol-
lowing initiation of an anticonvulsant, consistent with the low
rate of delayed seizures reported in other studies [4–6]. This sug-
gests that efﬁcacy – at least when measured by the incidence of
overt (as against non-convulsive) seizures – may not be a major
consideration in the selection of an agent for anticonvulsant pro-
phylaxis. In addition, the choice of anticonvulsant did not inﬂuence
the risk of DCI in our study. Only modiﬁed Fisher grade and seizure
1512 R.R. Karamchandani et al. / Journal of Clinical Neuroscience 21 (2014) 1507–1513prior to anticonvulsant use were statistically signiﬁcant associa-
tions with DCI in a multivariate logistic regression analysis. The
strong association of DCI and delayed infarction with occurrence of
seizure prior to anticonvulsant use is a particularly interesting
ﬁnding. Other studies have reported a similar association between
seizures at onset and DCI or poor outcome [19,20]. While the mech-
anism of such an association is unclear it is possible that seizure at
onset following aSAH identiﬁes a part of the brain at risk for focal
ischemia, and that more careful monitoring of this subgroup of
patients for the occurrence of delayed ischemia may be warranted.
Most importantly, the choice of anticonvulsant was not associ-
ated with functional outcome at ﬁrst follow-up in our study. The
multivariate analysis of the subgroup of patients treated with only
one anticonvulsant for the duration of the admission was particu-
larly important in this regard, in view of the high rate of crossover
from phenytoin to levetiracetam in the overall population. While
phenytoin was not associated with worse outcomes compared to
levetiracetam in our study, the high rate of crossover suggests that
levetiracetam may be the better tolerated agent, or at least more
convenient to use. Where a reason for crossover was documented,
the most common reasons were fever (a common occurrence fol-
lowing aSAH) and the difﬁculty with monitoring phenytoin levels
and maintaining a ‘‘therapeutic’’ level. The lack of association
between phenytoin use and poor outcomes in our study is not nec-
essarily contradictory to the ﬁnding of Naidech et al. that cumula-
tive ‘‘phenytoin burden’’ was associated with worse outcomes after
aSAH [7]. In the Naidech et al. study, phenytoin burden was studied
as a variable, based on daily measurement of serum levels, and
patients in the highest quartile of phenytoin burden, speciﬁcally,
were more likely to have worse outcomes [7]. In contrast, we
assessed any use of phenytoin for P72 hours as a variable and
did not measure phenytoin ‘‘burden’’. Our institutional practice
of avoiding aggressive supplementation to maintain ‘‘therapeutic’’
serum concentrations of phenytoin on the basis of daily testing of
levels may have resulted in a lower overall phenytoin burden. It is
possible therefore that higher cumulative phenytoin use over time
may be associated with negative cognitive effects, while more judi-
cious use may not be harmful.
Of note, because of our institutional protocol of routinely using
anticonvulsant prophylaxis in all patients for the duration of the
inpatient admission, the relative beneﬁts or harm of a strategy of
using no anticonvulsant prophylaxis, or short-duration anticonvul-
sant prophylaxis as recommended by some authors [15], could not
be evaluated. One study has identiﬁed the use of anticonvulsants
as a risk factor for poor outcomes following aSAH [21], while
another identiﬁed no beneﬁt in prevention of seizures in patients
undergoing aneurysm repair (including ruptured and unruptured
aneurysms) treated with anticonvulsants [22]. While these are
potentially important ﬁndings, no patients were treated with lev-
etiracetam in the study of aSAH patients [21], and in view of other
studies suggesting an increased risk of delayed seizures with short-
duration anticonvulsant use [8], further study may be required
before universal avoidance of anticonvulsant prophylaxis following
aSAH can be recommended as the standard of care.
The major limitation of our study is its retrospective nature. The
high crossover rate from phenytoin to levetiracetam limited the
sample size of patients treated exclusively with only one anticon-
vulsant to 175 and may have introduced a selection bias. We did,
however, study both the exposure to each anticonvulsant, as well
as the exclusive use of levetiracetam versus phenytoin, as risk fac-
tors for poor outcome and found no association. The relatively
small number of delayed seizures in our study, consistent with
other studies [4–6], limited our ability to detect potentially small
differences in efﬁcacy between the two anticonvulsants. Patients
in our study were not routinely monitored with cEEG, therefore
we could not draw conclusions on the effect of anticonvulsantprophylaxis on the occurrence of non-convulsive seizures. Assess-
ments of functional outcome beyond 6 months were not included
in our study. Magnesium infusions were routinely used at the same
ﬁxed dose in all patients during the period of study; this may have
had an effect on the outcomes analyzed, including the rate of sei-
zures. Lastly, although our analysis accounted for common con-
founders, other unmeasured confounders may have been present.
While a higher phenytoin burden may be associated with worse
outcomes following aSAH, our study is signiﬁcant in demonstrating
that the routine use of an alternate anticonvulsant, levetiracetam,
may not necessarily result in an overall improvement in outcomes.
While no difference in outcomes were seen, however, the high
crossover rate from phenytoin, along with the equivalent efﬁcacy
in seizure prevention seen in our study with levetiracetam, sug-
gests that levetiracetam may in fact be the preferred agent for rea-
sons of tolerance and/or convenience. In the absence of
randomized clinical trials in the speciﬁc setting of aSAH, levetirace-
tam may be a reasonable alternative to phenytoin for seizure
prophylaxis.
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